Research into Lipid Replacement Therapy for CFS
As covered in the
upcoming issue of the CFIDS Chronicle
(Vol. 19 Issue 3, Summer 2006)
Research evidence indicates that
diminished mitochondrial function caused by oxidation occurs during aging and in
fatiguing illnesses. When mitochondrial function is impaired, the net energy
available to cells is limited. There are a number of conditions and substances
that can weaken the mitochondria, but oxidation and damage of mitochondrial
membrane lipids can lead to a loss of electron transport function.
A report in the Spring 2006 edition of the Journal of
Chronic Fatigue Syndrome described clinical studies where lipid replacement
therapy (LRT) combined with antioxidants appeared to reduce fatigue levels and
improve mitochondrial function by protecting the membranes and replacing damaged
Concentrations of orally ingested lipids, such as in the
products NTFactor and Propax, diffuse through the gut, are transported via the
blood and deposited onto specific cell membrane receptors, where they are taken
into the cells.
In clinical studies, subjects using dietary LRT and
antioxidants experienced a 40 percent reduction in fatigue scores after eight
weeks. Researchers also observed a correlation between reductions in fatigue and
gains in mitochondrial function.
Though these studies are preliminary, the report suggests that
people with CSF may benefit from exploring LRT and antioxidant consumption as
one part of their overall treatment strategy.
[Editor’s note: This is one of
several studies covered in the “Research Briefs” section of the Summer 2006
CFIDS Chronicle. Other stories in this issue address
how people with CFS are using the Internet to reduce isolation, problems with
long-term disability insurance and implications of recent brain studies of CFS